New Drug for RDEB Skin Condition With Professor Mark Lowdell From The UK

Send us Fan MailIss rare disease journeImagine waking up every day knowing even a light touch could cause your skin to tear or blister. That’s the reality for children and adults living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) — a severe rare genetic condition where skin and mucous membranes are extremely fragile. In this episode of Rare Connection, host Joanna speaks with Professor Mark Lowdell — Chief Scientific Officer & Co-Founder of INmune Bio and Professor of Cell & Tissue Therapy at University College London — about a promising cell therapy called CORDStrom™, developed for RDEB and currently progressing through clinical development. GOSH Hospital site+1We discuss🔹 What RDEB is and how it affects daily life and long-term health MedlinePlus🔹 The science behind CORDStrom™ and its clinical trial results in pediatric RDEB patients inmunebio.com🔹 What it means to prepare a Biologics License Application (BLA) submission to the FDA and future regulatory milestones Patsnap Synapse🔹 The human stories behind the research and why this work matters for families living with rare disease💬 CONNECT & SHARE📌 Subscribe to Rare Connection — hit the button so you never miss an episode!👍 Like, Share & Comment — tell us what you thought or what you’d like to hear next!📌 Join the Rare Connection Facebook Group — a supportive space for patients, caregivers, and advocates.   https://www.facebook.com/groups/3802022513417876📌 Join the Addaotuve Kitchen Facebook Group — for people navigating multiple diets and shared meal ideas.  https://www.facebook.com/groups/13943332754051Support the show